You just read:

Duchesnay Inc. is seeking Health Canada's approval for ospemifene for the treatment of moderate to severe dyspareunia and vaginal dryness, symptoms of vulvar and vaginal atrophy, a component of genitourinary syndrome of menopause

News provided by

Duchesnay inc.

Jun 10, 2019, 10:00 ET